BioMarin Pharmaceutical (BMRN) News Today $57.48 +0.60 (+1.05%) Closing price 04:00 PM EasternExtended Trading$57.49 +0.01 (+0.02%) As of 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BMRN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Research Analysts Issue Forecasts for BMRN FY2026 EarningsBioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for BioMarin Pharmaceutical in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst O. Brayer anticipates that the biotechnology company will earn $June 10 at 9:17 AM | marketbeat.comBioMarin Pharmaceutical: Hold Rating Maintained Amid Competitive Pressures and New Data InsightsJune 10 at 6:53 AM | tipranks.comPallas Capital Advisors LLC Buys 22,527 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Pallas Capital Advisors LLC boosted its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 702.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,733 shares of the biotJune 10 at 5:59 AM | marketbeat.comToth Financial Advisory Corp Raises Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Toth Financial Advisory Corp increased its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 2,878.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,105 shares of the biotechnology cJune 10 at 4:59 AM | marketbeat.comWesbanco Bank Inc. Makes New Investment in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Wesbanco Bank Inc. bought a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 16,000 shares of the biotechnology company's stock, valJune 10 at 4:59 AM | marketbeat.comMerit Financial Group LLC Has $1.47 Million Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Merit Financial Group LLC increased its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 331.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 20,813 shares of the biotechnology cJune 7 at 4:31 AM | marketbeat.comGAMMA Investing LLC Boosts Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)GAMMA Investing LLC boosted its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 17,853.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 221,189 shares of theJune 7 at 4:09 AM | marketbeat.comWealth Enhancement Advisory Services LLC Purchases 17,340 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Wealth Enhancement Advisory Services LLC increased its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 295.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,201 shares of thJune 7 at 3:46 AM | marketbeat.comHere Are All 6 Stocks I've Bought Through 5 Months of 2025June 5, 2025 | fool.comUniversal Beteiligungs und Servicegesellschaft mbH Acquires New Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 159,000 shareJune 1, 2025 | marketbeat.comSummit Global Investments Purchases New Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Summit Global Investments acquired a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 49,488 shares of the biotecMay 31, 2025 | marketbeat.comCalifornia State Teachers Retirement System Grows Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)California State Teachers Retirement System grew its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 2.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 273,761 shares of the biotechnology company's stoMay 31, 2025 | marketbeat.com66,436 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Acquired by Lansforsakringar Fondforvaltning AB publLansforsakringar Fondforvaltning AB publ purchased a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 66,436 shares of the biotechnology company'May 30, 2025 | marketbeat.comPKO Investment Management Joint Stock Co Purchases New Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)PKO Investment Management Joint Stock Co bought a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 12,000 shares of theMay 30, 2025 | marketbeat.comSiemens Fonds Invest GmbH Takes $821,000 Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Siemens Fonds Invest GmbH bought a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 12,496 shares of the biotechnology company's stock, valued at approxMay 30, 2025 | marketbeat.comPolar Asset Management Partners Inc. Purchases New Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Polar Asset Management Partners Inc. acquired a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 14,900 shares of the biotechnology comMay 29, 2025 | marketbeat.comForum Financial Management LP Takes Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Forum Financial Management LP bought a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 4,531 shares of the biotechnology company's stock, vaMay 29, 2025 | marketbeat.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Acquired by Mackenzie Financial CorpMackenzie Financial Corp raised its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 203.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 220,661 shares of the biotechnology company's stMay 28, 2025 | marketbeat.comTidal Investments LLC Has $857,000 Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Tidal Investments LLC trimmed its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 57.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,039 shares of the biotechnology company's stock after seMay 28, 2025 | marketbeat.comLeading with purpose: Amy Wireman’s impact at BioMarin and beyond (video)May 28, 2025 | bizjournals.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 19.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutMay 27, 2025 | marketbeat.comQuantinno Capital Management LP Purchases Shares of 5,848 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Quantinno Capital Management LP bought a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 5,848 shares of the biotechnoMay 27, 2025 | marketbeat.comTwo Sigma Advisers LP Has $7.03 Million Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Two Sigma Advisers LP trimmed its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 41.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 107,014 shares of the biotechnoMay 26, 2025 | marketbeat.comVoloridge Investment Management LLC Boosts Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Voloridge Investment Management LLC raised its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 461.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 271,298 shares of the biotechnology company's stock after acquirinMay 25, 2025 | marketbeat.comWorldquant Millennium Advisors LLC Buys 214,546 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Worldquant Millennium Advisors LLC increased its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 337.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 278,118 shares of the biotechnology company's stMay 23, 2025 | marketbeat.com6,941 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Acquired by Focus Partners WealthFocus Partners Wealth purchased a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 6,941 shares of the biotechnology company's stock, valued at apMay 23, 2025 | marketbeat.comMIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 13,560 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 30.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 57,607 shares of the biotechnology compMay 22, 2025 | marketbeat.comINOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZYMay 21, 2025 | businesswire.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stake Boosted by Vestal Point Capital LPVestal Point Capital LP raised its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 115.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 860,000 shares of the biotechnology company's stock after purchasing an additional 460,000 shares dMay 21, 2025 | marketbeat.comSoleus Capital Management L.P. Makes New $65.82 Million Investment in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Soleus Capital Management L.P. acquired a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 1,001,400 sharesMay 21, 2025 | marketbeat.comTriglav Skladi D.O.O. Invests $1.09 Million in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Triglav Skladi D.O.O. bought a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 16,500 shares of the biotechnolMay 21, 2025 | marketbeat.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CAO Erin Burkhart Sells 1,786 SharesMay 21, 2025 | insidertrades.comSherbrooke Park Advisers LLC Buys Shares of 5,510 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Sherbrooke Park Advisers LLC bought a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 5,510 shares of the biotechnology company's stock, valued at approximaMay 21, 2025 | marketbeat.comGotham Asset Management LLC Lowers Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Gotham Asset Management LLC lessened its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 49.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 11,734 shares of the biotechnology company's stock after selliMay 21, 2025 | marketbeat.com12,496 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Bought by Siemens Fonds Invest GmbHSiemens Fonds Invest GmbH bought a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 12,496 shares of the biotechnology company's stock, valued at approximately $821,000. Several other iMay 20, 2025 | marketbeat.com14,900 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Purchased by Polar Asset Management Partners Inc.Polar Asset Management Partners Inc. bought a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm bought 14,900 shares of the biotechnology company's stock, valued at approximately $979,000May 20, 2025 | marketbeat.comNuveen Asset Management LLC Has $66.19 Million Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Nuveen Asset Management LLC lessened its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 17.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,006,922 shares of the bioMay 20, 2025 | marketbeat.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Rating of "Moderate Buy" by BrokeragesBioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) has earned an average rating of "Moderate Buy" from the twenty-three ratings firms that are currently covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a hold rating and seventeen have given a buy rating toMay 20, 2025 | marketbeat.comBioMarin: Inozyme Acquisition Falls Short Of Offsetting Looming Revenue Risks (Downgrade)May 19, 2025 | seekingalpha.comStrategic Acquisition of INZY Boosts BioMarin’s Growth Potential and Pipeline ExpansionMay 19, 2025 | tipranks.comRaiffeisen Bank International AG Invests $1.03 Million in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Raiffeisen Bank International AG acquired a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 15,658 shares of the biotechnology company's stock, valued at approximately $1,May 19, 2025 | marketbeat.comBioMarin Expands Rare Disease Portfolio with $270M Inozyme AcquisitionMay 18, 2025 | insidermonkey.comBioMarin Expands Rare Disease Portfolio with $270M Inozyme AcquisitionMay 18, 2025 | msn.com60,741 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Acquired by Point72 Europe London LLPPoint72 Europe London LLP purchased a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 60,741 shares of the biotechnology company's stMay 17, 2025 | marketbeat.comEnsign Peak Advisors Inc Decreases Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Ensign Peak Advisors Inc cut its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 8.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 61,868 shares of the biotechnology company's stock after selling 5,995 shares duriMay 17, 2025 | marketbeat.comBioMarin Pharmaceutical Inc.: BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme PharmaMay 16, 2025 | finanznachrichten.deBioMarin to Acquire Inozyme Pharma for $270 MillionMay 16, 2025 | marketwatch.comBMRN Q1 Earnings Call: BioMarin Outperforms on Revenue and Expands Pipeline ProgressMay 16, 2025 | finance.yahoo.comBioMarin Pharmaceutical: Balancing Opportunities and Risks Amid Inozyme Acquisition and Market ChallengesMay 16, 2025 | tipranks.comBioMarin Pharmaceutical’s Strategic Growth and Market Potential: A Buy Rating by Yun ZhongMay 16, 2025 | tipranks.com Get BioMarin Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address BMRN Media Mentions By Week BMRN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BMRN News Sentiment▼1.290.68▲Average Medical News Sentiment BMRN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BMRN Articles This Week▼1012▲BMRN Articles Average Week Get BioMarin Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ALNY News Today BIIB News Today UTHR News Today INCY News Today NBIX News Today EXEL News Today EXAS News Today RGEN News Today HALO News Today MDGL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BMRN) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.It could very well mark the beginning of a new multitrillion-dollar industrial revolution. Up until now, we...Weiss Ratings | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredWhy 2026 will be a disaster for many Americans2025 Market Crash The first-quarter stock crash left investors wondering what lies ahead. Today 50-year Wal...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
